Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is one of the 12 Best Performing Stocks in the Last 3 Months. On October 16, Oppenheimer raised its price target on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) from $115 to $250 and kept an Outperform rating.
This decision came after positive topline results from Praxis Precision Medicines, Inc.’s 3 Essential3 trial of ulixacaltamide for essential tremor (ET), a nervous system condition that causes involuntary shaking, mostly in the hands and arms. There is currently no approved treatment for this condition.
The drug met all endpoints in Study 1 and its pre-specified primary endpoint in Study 2. Ulixacaltamide was generally safe and well-tolerated, showing no serious drug-related side effects.
Oppenheimer expects Praxis Precision Medicines, Inc. to submit a New Drug Application in early 2026, which could potentially see the drug being launched commercially in 2027 after approval by the FDA.
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders.
READ NEXT: 10 Best American AI Stocks to Buy According to Analysts and 11 Dirt Cheap Stocks to Buy According to Analysts.
This article is originally published at Insider Monkey.